Rajal Sharma,Katerina Politi
Rajal Sharma
Treatments for lung cancer have advanced significantly over the last 2 decades, improving survival and long-term outcomes. However, lung cancer mortality remains high, and cures for metastatic disease have remained elusive. Here, we outline...
Medical Management of Non-Small Cell Lung Cancer Brain Metastases in the Modern Era [0.03%]
现代非小细胞肺癌脑转移的医学管理
Benjamin Y Lu,Sarah B Goldberg
Benjamin Y Lu
Brain metastases are a common complication among patients with non-small cell lung cancer and are historically associated with significant morbidity and limited survival. Although surgery and radiation therapy remain essential pillars in th...
Optimizing the Care of Patients With Locally Advanced NSCLC With Multimodality Therapy [0.03%]
局部晚期非小细胞肺癌多模式治疗患者的护理优化
Mohammed Mohammed,Neal S McCall,Kristin A Higgins
Mohammed Mohammed
Unresectable, locally advanced nonsmall cell lung cancer (LA‑NSCLC) accounts for ∼20% to 30% of newly diagnosed cases of NSCLC and remains associated with poor long‑term outcomes. Concurrent chemoradiotherapy (cCRT) has long been the the...
Early-Stage NSCLC: Novel Surgical Techniques and Neoadjuvant, Adjuvant, and Perioperative Therapies [0.03%]
早期非小细胞肺癌的新型外科手术方法及新辅助、辅助和围术期治疗
So Yeon Kim,Gavitt Woodard
So Yeon Kim
Neoadjuvant and perioperative chemoimmunotherapy has transformed the treatment of tumors >4 cm or node-positive disease (stage II to IIIA, AJCC 8th edition) in non-small cell lung cancer (NSCLC). Compared with neoadjuvant chemotherapy alone...
Lung Cancer Biomarker Testing: IHC, Tissue Genomics, Digital Pathology, and ctDNA [0.03%]
肺癌生物标志物检测:IHC、组织基因组学、数字病理和ctDNA
Humberto E Trejo Bittar,Sanja E Dacic
Humberto E Trejo Bittar
Testing for predictive biomarkers in lung cancer has evolved to integrate immunohistochemistry, tissue-based next-generation sequencing (NGS), and liquid biopsy. Tissue-based NGS remains the foundation for comprehensive genomic profiling, e...
The Quest to Cure Metastatic Non-Small Cell Lung Cancer With Immunotherapy [0.03%]
免疫疗法治疗转移性非小细胞肺癌的探索
Daniel Boiarsky,Natalie Vokes
Daniel Boiarsky
The introduction of immune checkpoint inhibitors targeting the programmed death-1 (PD-1) axis represented a major therapeutic advance, enabling long-term survival, and even cure, in a subset of patients, an outcome previously considered una...
Yunan Nie,Frederick H Wilson
Yunan Nie
Oncogenic gene fusions define a clinically important subset of non-small cell lung carcinoma (NSCLC) for which targeted therapies have transformed outcomes. Over the past 15 years, successive generations of tyrosine kinase inhibitors (and m...
Tämer El Saadany,Núria Aeschlimann,Adrian Sacher
Tämer El Saadany
KRAS driver mutations have classically been considered undruggable by direct inhibitors in non-small cell lung cancer (NSCLC) as well as other solid tumors. However, recent advances have led to the first successful direct KRAS inhibitors, b...
A Quarter Century of Transformation: Integrating Molecular Stratification and Immune Modulation Across the Continuum of Non-Small-Cell Lung Cancer [0.03%]
肺癌分子分型和免疫微环境的时空演变及克服免疫治疗耐药策略
Amin H Nassar,Jad Halawi,Roy S Herbst
Amin H Nassar
Non-small-cell lung cancer (NSCLC) has seen a paradigm shift over the past quarter century driven by systematic molecular characterization, the advent of targeted therapies, the implementation of low-dose CT screening, and the integration o...
Treatment of Non-Small Cell Lung Cancer: A Clinical Model for Solid Tumors [0.03%]
非小细胞肺癌的治疗:实体瘤临床模型的例子
Sarah B Goldberg,Roy S Herbst
Sarah B Goldberg